| 纯度 | >85%SDS-PAGE. |
| 种属 | mouse |
| 靶点 | PDK4 |
| Uniprot No | O70571 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 138-368aa |
| 氨基酸序列 | ILEYKDTCTVDPVTNQNLQYFLDRFYMNRISTRMLMNQHILIFSDSKTGN PSHIGSIDPNCDVVAVVQDAFECAKMLCDQYYLTSPELNLTQVNGKFPGQ PIHIVYVPSHLHHMLFELFKNAMRATVEHQENRPSLTPVEATVVLGKEDL TIKISDRGGGVPLRITDRLFSYTYSTAPTPVMDNSRNAPLAGFGYGLPIS RLYAKYFQGDLNLYSMSGYGTDAIIYLKALS |
| 预测分子量 | 30 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
1. **"Recombinant PDK4 Expression and Characterization in Escherichia coli"**
*Authors: Zhang Y, et al.*
**摘要**: 研究报道了在大肠杆菌中高效表达并纯化重组人源PDK4蛋白，通过优化诱导条件及纯化步骤获得高活性蛋白，验证其激酶活性及对丙酮酸脱氢酶复合体的抑制作用。
2. **"Structural Insights into PDK4 Regulation by Small Molecules via Recombinant Protein Crystallography"**
*Authors: Lee S, Kim J.*
**摘要**: 利用重组PDK4蛋白进行晶体结构解析，揭示其与抑制剂DCA(二氯乙酸)的结合位点，为靶向PDK4的代谢性疾病治疗提供结构基础。
3. **"Functional Analysis of PDK4 in Cardiac Metabolism Using Recombinant Adenoviral Delivery"**
*Authors: Wang H, et al.*
**摘要**: 构建重组腺病毒载体表达PDK4蛋白，验证其在心肌细胞中调控葡萄糖氧化向脂肪酸代谢的转换，揭示PDK4在心力衰竭中的潜在作用机制。
4. **"Development of a PDK4 Activity Assay Using Purified Recombinant Protein for Drug Screening"**
*Authors: Tanaka R, et al.*
**摘要**: 开发基于重组PDK4蛋白的高通量激酶活性检测体系，用于筛选2型糖尿病药物，证明PDK4抑制剂可增强细胞葡萄糖氧化能力。
PDK4 (pyruvate dehydrogenase kinase 4) is a mitochondrial enzyme that plays a critical role in cellular energy metabolism by regulating the activity of the pyruvate dehydrogenase complex (PDC). PDC catalyzes the conversion of pyruvate to acetyl-CoA, a key step linking glycolysis to the tricarboxylic acid (TCA) cycle. PDK4 phosphorylates and inhibits PDC, effectively shifting cellular metabolism from glucose oxidation to fatty acid utilization—a metabolic adaptation crucial during fasting, exercise, or stress. Dysregulation of PDK4 expression is implicated in metabolic disorders, including diabetes, obesity, and cancer, where altered fuel preference supports disease progression.
Recombinant PDK4 protein is produced using genetic engineering techniques, typically expressed in bacterial (e.g., *E. coli*) or mammalian cell systems to ensure proper folding and functional activity. Its production enables detailed biochemical studies, such as enzyme kinetics, structural analysis, and interaction mapping with PDC or small-molecule inhibitors. Researchers also leverage recombinant PDK4 to explore its role in pathological conditions; for instance, elevated PDK4 levels in diabetes contribute to insulin resistance by impairing glucose uptake, while cancer cells exploit PDK4 upregulation to favor glycolysis (the Warburg effect) even under aerobic conditions.
Pharmaceutical interest in PDK4 centers on developing inhibitors to modulate metabolic pathways. Compounds like dichloroacetate (DCA) target PDKs to reactivate PDC, offering therapeutic potential for metabolic diseases or cancers reliant on glycolytic metabolism. Recombinant PDK4 serves as a vital tool for high-throughput screening of such compounds and validating drug mechanisms. Additionally, its use in animal models helps elucidate tissue-specific metabolic regulation. As a reagent, recombinant PDK4 is characterized for purity, stability, and enzymatic activity via SDS-PAGE, Western blot, and activity assays, ensuring reproducibility in experimental settings.
×
